Figure 1 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Le résumé fourni par la source
Overview of colorectal cancer and urothelial cancer cohorts. A and B, Bar plots showing the number of NOUS-209 FSMs detected in each sample of colorectal cancer and urothelial cancer cohorts. The median number of mutations is indicated by the blue dashed line (colorectal cancer = 57; urothelial cancer = 24). C, Venn diagram illustrating the overlap of NOUS-209 FSMs between colorectal cancer and urothelial cancer. D and E, Bar plots displaying the MSI scores in the colorectal cancer and urothelial cancer cohorts, respectively. The blue dashed line represents the recommended threshold of MSI score (20%) for classifying a sample as MSI. Lighter bars indicate samples classified as MSS. CRC, colorectal cancer; UC, urothelial cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Figure 1 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
- Date Crossref
- 02/04/2026
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.